Sarepta names Michael Severino as new CEO
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sarepta Therapeutics on Monday named Michael Severino, formerly CEO of Tessera Therapeutics, as its new chief executive, with the appointment effective Tuesday.
- Severino replaces Doug Ingram, who announced earlier this year he planned to retire after leading the Duchenne muscular dystrophy biotech for nearly a decade.
- Under Ingram's tenure, Sarepta secured three Duchenne treatment approvals but has faced ongoing questions about how effective those therapies are and regulatory scrutiny over the safety of its gene therapy.
- Sarepta's share price has tanked from where it stood at the beginning of 2025, the company noted in announcing the leadership change.
Why it matters: Severino takes over a company whose shares have tanked since the start of 2025 and that faces both efficacy questions on its three approved Duchenne treatments and regulatory scrutiny over its gene therapy's safety. His gene-editing leadership at Tessera brings directly relevant technical expertise to a Duchenne-focused gene therapy maker navigating simultaneous commercial and regulatory headwinds.
